<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63C3968A-F903-4D7A-8EFB-D9A237129852"><gtr:id>63C3968A-F903-4D7A-8EFB-D9A237129852</gtr:id><gtr:name>Marie Curie</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63C3968A-F903-4D7A-8EFB-D9A237129852"><gtr:id>63C3968A-F903-4D7A-8EFB-D9A237129852</gtr:id><gtr:name>Marie Curie</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8D01AB24-F469-47FB-8EF5-1C4EAEC5D828"><gtr:id>8D01AB24-F469-47FB-8EF5-1C4EAEC5D828</gtr:id><gtr:firstName>Lucy</gtr:firstName><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800391"><gtr:id>069B2783-6011-45A0-A658-4D879CB79B71</gtr:id><gtr:title>Analysis of CD8+ T cell quality in Hepatitis C using novel MHC peptide tetramers.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800391</gtr:grantReference><gtr:abstractText>Hepatitis C virus (HCV) infects nearly 200 million people worldwide. Once infected the body mounts an immune response, which is variably successful. Sometimes the immune response can clear the virus, however in most cases it fails to do so and the virus can then go on to cause severe liver damage. The quality of the immune response may determine the outcome of the infection. One aspect of the quality is how sensitive the key immune cells (T cells) are to low amounts of virus - the more sensitive cells might be more efficient in controlling the virus. We have developed new methods for measuring the quality of T cells in different people, including healthy volunteers receiving an experimental vaccine against HCV. We aim to create a panel of new tetramers, specially designed to identify the high and low quality cells in different donors, and look at how these correlate with the outcome of infection, or change over time. In doing this we hope to be able to better understand why some people clear the virus and others do not, and also to design better vaccines or immune treatments in the future.</gtr:abstractText><gtr:technicalSummary>Background: Hepatitis C virus (HCV) sets up persistence in the majority of those infected. A minority, however, are able to control the virus long term. The innate and adaptive responses which determine this have been defined to some extent, but we still do not understand the detailed differences between successful and unsuccessful responses. CD8+ T cells have been shown to be important in control of HCV, and specific HLA alleles such as HLA B27 and A3 have been shown to be protective in certain cohorts. We propose to use MHC-peptide tetramers, fluorescent complexes which bind the T cell receptor (TCR) specifically, to define the CD8 dependence and TCR affinity of individual responses from HCV infected donors and controls. 

Methodology: The Oxford lab have recently developed a set of tetrameric complexes which allow direct evaluation of the affinity of the T cells for peptide antigen (magic tetramers). This is achieved by modification of the CD8 binding site on MHC allowing identification of specific T cell subpopulations which are CD8 independent or hyper-dependent. This links closely with the triggering threshold for such cell populations in functional assays.

Design: The lab has identified cohorts of patients where such an approach can be exploited to identify the association between TCR affinity and clinical outcome. These include patients with chronic and acute infection, across a range of HLAs including patients with HLA-B27, the best defined protective allele. Functional assays will also be performed in concert with tetramer analyses.

Aims: I aim to use these tools and patients to define:
1. Changes in the quality (affinity) of responses over time in acute disease.
2. Differences in quality between different patient groups.
3. Differences in quality between different peptides/HLAs. 
4. Differences in quality between different peptides/HLAs in a new cohort of healthy volunteers to be vaccinated with a novel HCV vaccine, designed specifically to elicit CD8+ T cells through novel viral vectors. (Funding for such a trial is already established and it is due to start in 2008 pending final regulatory approvals).

Opportunities: We aim to use novel tools to define the functionality of antiviral CD8+ T cells in relation to the outcome of persistent infection. This has implications for defining the outcome of HCV, its treatment and vaccination but also beyond this to other significant persistent viruses, including HBV and HIV, where the host-virus balance may hinge on similar aspects of T cell quality.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>167767</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:description>Analysis of microarray data from CD161++CD8+ T cells from cord blood and CD8aa T cells from adult peripheral blood</gtr:description><gtr:id>1EFB1319-E1A5-4EFD-B660-8C7A6E34A754</gtr:id><gtr:impact>Data from this collaboration is included in the paper currently pre-published in Blood (see previous section for details).</gtr:impact><gtr:outcomeId>FZwNjctTpP2-1</gtr:outcomeId><gtr:partnerContribution>Our collaborative partners provided bioinformatics expertise.</gtr:partnerContribution><gtr:piContribution>We provided the raw data for this collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Study of CD161++CD8+ T cells in infants</gtr:description><gtr:id>B67F4DF2-7068-4C30-8351-D923B56477A9</gtr:id><gtr:impact>We have a paper pre-published online in Blood (see details in previous section) that has included data from this collaboration.</gtr:impact><gtr:outcomeId>PPxyXSjfTJB-1</gtr:outcomeId><gtr:partnerContribution>The collaboration provided samples from healthy infants to study.</gtr:partnerContribution><gtr:piContribution>We used the samples to perform FACS analysis to study the CD161++CD8+ T cell subset.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Study of intra-hepatic CD161++CD8+ T cells</gtr:description><gtr:id>0C727C5C-B7EA-4EAA-B098-9AB43861895A</gtr:id><gtr:impact>Data obtained from this collaboration is included in the paper which is pre-published in Blood (see previous section for details).</gtr:impact><gtr:outcomeId>qGEfHEaPuza-1</gtr:outcomeId><gtr:partnerContribution>This collaboration provided samples of liver derived lymphocytes.</gtr:partnerContribution><gtr:piContribution>We used the samples provided for FACS analysis of intra-hepatic CD161++CD8+ T cell populations</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Marie Curie</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Marie Curie Research Institute</gtr:department><gtr:description>Study of Mucosal Associated Invariant T cells and their relationship to CD161++CD8+ T cells</gtr:description><gtr:id>28C5B624-8BF1-45EA-96B0-BA0A2B386E60</gtr:id><gtr:impact>The data obtained from this collaboration is included in the paper pre-published in Blood (see previous section for details).</gtr:impact><gtr:outcomeId>jR9SDpxEhe9-1</gtr:outcomeId><gtr:partnerContribution>This collaboration provided an antibody against the MAIT cell T cell receptor (Va7.2), which was not commercially available at the time.</gtr:partnerContribution><gtr:piContribution>We used the antibody provided to study the CD161++CD8+ T cell population.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Gastroenterology Harvard</gtr:department><gtr:description>Study of peripheral and intra-hepatic CD161++CD8+ T cells in hepatitis C</gtr:description><gtr:id>8F7AA165-ADD0-434C-B561-E3FE5AB9E162</gtr:id><gtr:impact>Data obtained from this collaboration is in the paper currently pre-published in Blood (see previous section).</gtr:impact><gtr:outcomeId>CYeuqi9eUqM-1</gtr:outcomeId><gtr:partnerContribution>This collaboration provided paired peripheral blood and intrahepatic lymphocyte samples for FACS analysis.</gtr:partnerContribution><gtr:piContribution>We used the samples provided to study the CD161++CD8+ T cell population in the peripheral circulation and in the liver in chronic hepatitis C.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C47209BB-2451-4798-8E67-6CB23B92445E</gtr:id><gtr:title>Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15677618d190f121dd682fd99401149d"><gtr:id>15677618d190f121dd682fd99401149d</gtr:id><gtr:otherNames>Billerbeck E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>TNkZrZPWujj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3F14C3A-FC9D-4E6C-B96F-47824156156D</gtr:id><gtr:title>T cell sensitivity and the outcome of viral infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e010a90f68a03e6f502ca741eaf42f"><gtr:id>01e010a90f68a03e6f502ca741eaf42f</gtr:id><gtr:otherNames>Walker LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>Cn9mrmTipJz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED9EB141-FB74-4F61-A0F2-4CA2E91A82A1</gtr:id><gtr:title>Human MAIT and CD8aa cells develop from a pool of type-17 precommitted CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e010a90f68a03e6f502ca741eaf42f"><gtr:id>01e010a90f68a03e6f502ca741eaf42f</gtr:id><gtr:otherNames>Walker LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>NviJKetpGH4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800391</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>